var data={"title":"Meningococcal serogroup C polysaccharide tetanus toxoid conjugate vaccine (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Meningococcal serogroup C polysaccharide tetanus toxoid conjugate vaccine (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/791886?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=meningococcal-serogroup-c-polysaccharide-tetanus-toxoid-conjugate-vaccine-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Meningococcal serogroup C polysaccharide tetanus toxoid conjugate vaccine (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45950232\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>NeisVac-C Vaccine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46022104\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vaccine;</li>\n      <li>\n        Vaccine, Inactivated (Bacterial)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46021244\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary immunization:</b> IM: 0.5 mL/dose as a single dose. <b>Note:</b> The need for a booster dose in individuals who received a single primary dose at age &ge;12 months has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Post exposure management (close contacts) or outbreak control (off-label use) (NACI 2012):</b> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Unvaccinated: 0.5 mL/dose immediately after exposure (monovalent or quadrivalent vaccine may be used)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Previously vaccinated: If vaccinated at &lt;1 year of age or if at high risk for invasive meningococcal disease, re-vaccinate with 0.5 mL/dose if &ge;4 weeks since last dose; otherwise re-vaccinate if at least 1 year since last dose (monovalent or quadrivalent vaccine may be used).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46021243\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Immunization:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Primary immunization: </i>IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 2 to &lt;4 months: 0.5 mL/dose; administer for a total of 2 doses at least 2 months apart (second dose should be administered at &gt;5 months of age).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;4 months, Children, and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Booster immunization:</i> IM: Infants who have completed the primary immunization series may receive 0.5 mL/dose as a single dose administered at 12 to 13 months of age and at least 6 months after the previous NeisVac-C vaccination. The need for a booster dose in individuals who received a single primary dose at &ge;12 months of age has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Post exposure management (close contacts) or outbreak control (off-label use) (NACI 2012):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Infants 2 to &lt;12 months:</i> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Unvaccinated: 0.5 mL/dose immediately after exposure; then complete routine series </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Previously vaccinated: Re-vaccinate with 0.5 mL/dose if &ge;4 weeks since last dose; then complete routine series if necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Children and Adolescents:</i> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Unvaccinated: 0.5 mL/dose immediately after exposure (monovalent vaccine recommended for children 1 to 10 years; monovalent or quadrivalent vaccine may be used in individuals &ge;11 years)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Previously vaccinated: If vaccinated at &lt;1 year of age or if at high risk for invasive meningococcal disease, re-vaccinate with 0.5 mL/dose if &ge;4 weeks since last dose; otherwise re-vaccinate if at least 1 year since last dose (monovalent vaccine recommended for children 1 to 10 years; monovalent or quadrivalent vaccine may be used in individuals &ge;11 years)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46021245\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46021246\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46021252\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension, Prefilled Syringe, Intramuscular:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">NeisVac-C: 10 mcg of Serogroup C polysaccharide per 0.5 mL (0.5 mL) [conjugated to tetanus toxoid protein carrier]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46021251\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46021248\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Intramuscular: Administer into the anterolateral thigh in infants and the deltoid area in children, adolescents, and adults. Do not administer IV or subcutaneously. Shake vaccine prior to use. Do not administer if particulate matter or discoloration is noted. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45950236\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningococcal disease prevention: </b>To provide active immunization against invasive meningococcal disease and/or septicemia caused by <i>N. meningitidis</i> serogroup C in infants &ge;2 months, children, adolescents, and adults</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">The National Advisory Committee on Immunization (NACI) recommends routine vaccination in healthy infants &ge;2 months (per provincial/local schedules), children, adolescents, and young adults. Selection of meningococcal vaccination to be based upon serogroups(s). NACI recommendations for persons considered to be at an increased risk for meningococcal disease:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chemoprophylaxis and immunoprophylaxis:</i> Selection of meningococcal vaccination to be based upon serogroup(s):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Individuals living in the same household, share sleeping arrangements, or with close contact (eg, kissing, shared cigarettes, shared eating or drinking utensils) of infected patient</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Employees and children of nursery schools or day care</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immunoprophylaxis:</i> Selection of meningococcal vaccination to be based upon serogroup(s):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents and young adults</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Laboratory workers routinely exposed to isolates of <i>N. meningitidis</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Military recruits</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Persons traveling to or who reside in countries where <i>N. meningitidis</i> is hyperendemic or epidemic, particularly if contact with local population will be prolonged. Use of a monovalent vaccine may not be appropriate based upon the serogroup prevalence in the region of travel.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Persons with terminal complement component deficiencies</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Persons with anatomic or functional asplenia, including sickle cell disease</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Use is also recommended during meningococcal outbreaks caused by serogroup C.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chemoprophylaxis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Health care workers with intensive unprotected contact with infected patients</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Airline passengers sitting directly next to an infected patient for duration of at least 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Close contacts of a case of invasive meningococcal disease from 7 days before onset of symptoms to 24 hours after onset of effective treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Close contacts of a case of invasive meningococcal disease due to serogroups not present in meningococcal vaccines, or when the serogroup in the index case has not been determined</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Previously vaccinated close contacts who do not meet re-vaccination criteria (refer to NACI guidelines)</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">See NACI guidelines for specific drug treatment at http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-meni-eng.php</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45950237\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Post exposure management (close contacts) or outbreak control of meningococcal disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46056565\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Irritability (infants and children: 22% to 53%), disturbed sleep (3% to 8%; infants and children: 12% to 53%), drowsiness (3% to 8%; infants and children: 12% to 53%), sleep disorder (35%), headache (7% to 26%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia (infants: 27%; children: 1% to 7%), diarrhea (infants: 12%; children: 3% to 5%), nausea (infants: 12%; children: 3% to 5%), vomiting (infants: 12%; children: 3% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Severe hypersensitivity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Pain at injection site (14% to 71%), application site induration (53%), injection site reaction (redness; 5% to 50%), swelling at injection site (8% to 31%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Limb pain (32%; children: 2%), myalgia (older children and adults: 6% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (55%), crying (infants and children: 22% to 53%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Apnea (premature infants), arthralgia, convulsions (including febrile), dizziness, hypoesthesia, hypotonia (infants), immune thrombocytopenia, lymphadenopathy, paresthesia (infants), pruritus, seizure, skin rash, syncope, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46021235\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to meningococcal group C-tetanus toxoid (TT) conjugate vaccine or any component of the formulation including tetanus toxoid.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46021236\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]; NACI 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]; NACI 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines. Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin, 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Apnea has been reported following IM vaccine administration in premature infants; consider monitoring respiratory status for 48 to 72 hours after administration. In general, vaccination should not be withheld or delayed due to respiratory concerns. Preterm infants should be vaccinated at the same chronological age as full-term infants (ACIP [Kroger 2017]; NACI 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Vaccine has not been studied in elderly patients (&ge;65 years of age).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen prior to vaccination to prevent fever decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: NACI recommends use of monovalent conjugate C, quadrivalent, or multicomponent meningococcal vaccine in healthy individuals and use of a quadrivalent conjugate or multicomponent meningococcal vaccine in high-risk individuals (NACI 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Meningococcal infections: Not to be used to treat meningococcal infections or to provide immunity against <i>N. meningitidis</i> serogroups other than group C.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tetanus infection: Vaccine is not intended for immunization against tetanus. Tetanus vaccination should still be administered as regularly scheduled.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45785802\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45785799\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=106317&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46021233\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Has not been studied in pregnancy. According to the NACI, the use of conjugated meningococcal vaccines should be considered in pregnant women in circumstances such as travel to high risk areas or if indicated as post-exposure prophylaxis against a vaccine preventable strain or during an outbreak (NACI 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46021234\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if this vaccine is found in breast milk. According to the NACI, inactivated vaccines, such as conjugate or multicomponent meningococcal vaccines, may be administered to women who are breast-feeding (NACI 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46021250\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2017]; NACI 2013). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46021240\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Induces immunity against meningococcal disease via the formation of bactericidal antibodies directed toward the polysaccharide capsular components of <i>Neisseria meningitidis</i> serogroup C.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46123472\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>NeisVac (FR);</li>\n      <li>NeisVac-C (AR, AT, AU, BE, CH, CL, CY, CZ, DE, DK, EE, ES, FI, GB, GR, HU, IS, IT, LT, LU, LV, MT, NL, NO, NZ, PL, PT, RO, SE, SI, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Canadian National Advisory Committee on Immunization (NACI). Canadian Immunization Guide, 2012. http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-eng.php. Accessed December 10, 2015</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian National Advisory Committee on Immunization (NACI). Canadian Immunization Guide, 2013. http://www.phac-aspc.gc.ca/publicat/cig-gci/p01-07-eng.php#post. Accessed December 10, 2015</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NeisVac-C (meningococcal group C-TT conjugate vaccine, adsorbed). Kirkland, Quebec, Canada: Pfizer Canada Inc; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al. Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials. <i>Lancet</i>. 2009;374(9698):1339-1350<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meningococcal-serogroup-c-polysaccharide-tetanus-toxoid-conjugate-vaccine-united-states-not-available-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 106317 Version 17.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F45950232\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F46022104\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F46021244\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F46021243\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F46021245\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F46021246\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F46021252\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F46021251\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F46021248\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45950236\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F45950237\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F46056565\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F46021235\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F46021236\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45785802\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45785799\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F46021233\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F46021234\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F46021250\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F46021240\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F46123472\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/106317|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=meningococcal-serogroup-c-polysaccharide-tetanus-toxoid-conjugate-vaccine-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Meningococcal serogroup C polysaccharide tetanus toxoid conjugate vaccine (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}